News | March 25, 2026
FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Subscribe To Our Newsletter & Stay Updated
